FiercePharma · 29m
With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight
When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit managers (PBMs) often commands at least some of the attention. | At the Senate committee hearing on Novo Nordisk's prices for Ozempic and Wegovy,
Benzinga.com · 11h
'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
Novo Nordisk 's NVO CEO Lars Fruergaard Jorgensen, has revealed that their diabetes medication and often hailed as a “miracle” weight loss drug, Ozempic will soon be eligible for U.S. government price negotiations, potentially within the next year.
Bloomberg L.P. · 1d
Novo CEO Blames Ozempic’s High Cost on Drug Middlemen’s Tactics
Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of blockbuster drugs Ozempic and Wegovy when he appears Tuesday before a congressional committee led by Senator Bernie Sanders: It’s the middlemen.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results